Have a feature idea you'd love to see implemented?
Let us know!
VERU Veru Inc
Price (delayed)
$0.6279
Market cap
$91.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.33
Enterprise value
$66.88M
Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111,
Highlights
The EPS has soared by 79% YoY and by 18% from the previous quarter
The net income has soared by 68% YoY and by 3.7% from the previous quarter
The equity has soared by 76% YoY but it has contracted by 17% from the previous quarter
VERU's gross profit is down by 28% year-on-year but it is up by 2.3% since the previous quarter
The quick ratio has contracted by 26% from the previous quarter
The gross margin has contracted by 23% YoY and by 2.1% from the previous quarter
Key stats
What are the main financial stats of VERU
Market
Valuations
Earnings
Shares outstanding
146.38M
Market cap
$91.91M
Enterprise value
$66.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.44
Price to sales (P/S)
6.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.75
Revenue
$14.09M
EBIT
-$38.65M
EBITDA
-$38.38M
Free cash flow
-$27.12M
Per share
Balance sheet
Liquidity
EPS
-$0.33
Free cash flow per share
-$0.19
Book value per share
$0.26
Revenue per share
$0.1
TBVPS
$0.39
Total assets
$64.63M
Total liabilities
$27.01M
Debt
$4.11M
Equity
$37.62M
Working capital
$27.86M
Debt to equity
0.11
Current ratio
3.62
Quick ratio
2.9
Net debt/EBITDA
0.65
Margins
Efficiency
Dividend
EBITDA margin
-272.4%
Gross margin
33.4%
Net margin
-284.8%
Operating margin
-281.1%
Return on assets
-60.1%
Return on equity
-104.2%
Return on invested capital
-174.9%
Return on capital employed
-71.6%
Return on sales
-274.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VERU stock price
How has the Veru stock price performed over time
Intraday
0.42%
1 week
-0.16%
1 month
-27.95%
1 year
-37.12%
YTD
-12.79%
QTD
-18.35%
Financial performance
How have Veru's revenue and profit performed over time
Revenue
$14.09M
Gross profit
$4.71M
Operating income
-$39.61M
Net income
-$40.13M
Gross margin
33.4%
Net margin
-284.8%
The operating income has surged by 70% year-on-year and by 7% since the previous quarter
The net income has soared by 68% YoY and by 3.7% from the previous quarter
The company's operating margin has surged by 68% YoY and by 11% QoQ
VERU's net margin has surged by 66% year-on-year and by 8% since the previous quarter
Growth
What is Veru's growth rate over time
Valuation
What is Veru stock price valuation
P/E
N/A
P/B
2.44
P/S
6.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.75
The EPS has soared by 79% YoY and by 18% from the previous quarter
The equity has soared by 76% YoY but it has contracted by 17% from the previous quarter
The P/B is 56% below the 5-year quarterly average of 5.5 but 6% above the last 4 quarters average of 2.3
VERU's price to sales (P/S) is 31% less than its 5-year quarterly average of 9.4 but 5% more than its last 4 quarters average of 6.2
Veru's revenue has decreased by 6% YoY but it has increased by 4.5% QoQ
Efficiency
How efficient is Veru business performance
The return on invested capital has surged by 85% year-on-year and by 9% since the previous quarter
The ROS has soared by 67% YoY and by 7% from the previous quarter
Veru's ROE has soared by 65% YoY and by 14% from the previous quarter
The ROA has soared by 56% YoY and by 4.6% from the previous quarter
Dividends
What is VERU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VERU.
Financial health
How did Veru financials performed over time
The total assets is 139% more than the total liabilities
Veru's current ratio has soared by 190% YoY but it has decreased by 23% from the previous quarter
The company's total liabilities fell by 34% YoY
VERU's debt is 89% smaller than its equity
The equity has soared by 76% YoY but it has contracted by 17% from the previous quarter
The debt to equity has dropped by 52% year-on-year but it is up by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.